Efficacy of Itraconazole in Blastomycosis in a Murine Model and Comparison with Ketoconazole
Authors:
Abstract
Summary: Mice were infected intranasally with B. dermatitidis yeasts, and after infection treated orally. Itraconazole 50–150mg/kg/day was protective (prolonged survival) against lethal infection, although the infection was not sterilized. Itraconazole was approximately 3 times as potent as ketoconazole. These results suggest advantages for itraconazole therapy clinically.Keywords
This publication has 8 references indexed in Scilit:
- Initial Experience in Therapy for Progressive Mycoses with Itraconazole, the First Clinically Studied TriazoleClinical Infectious Diseases, 1987
- Study of Current and New Drugs in a Murine Model of Acute Paracoccidioidomycosis *The American Journal of Tropical Medicine and Hygiene, 1985
- Treatment of Systemic Mycoses with Ketoconazole: Emphasis on Toxicity and Clinical Response in 52 PatientsAnnals of Internal Medicine, 1983
- Disposition of ketoconazole, an oral antifungal, in humansAntimicrobial Agents and Chemotherapy, 1982
- Molecular Modifications of Imidazole Compounds: Studies of Activity and Synergy in Vitro and of Pharmacology and Therapy of Blastomycosis in a Mouse ModelClinical Infectious Diseases, 1980
- MOUSE MODEL OF PULMONARY BLASTOMYCOSIS - UTILITY, SIMPLICITY, AND QUANTITATIVE PARAMETERS1978
- Statistics1977
- Antimicrobial Susceptibility Testing of Yeasts: a Turbidimetric Technique Independent of Inoculum SizeAntimicrobial Agents and Chemotherapy, 1976